Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026)

Jade Biosciences' Net Cash Flow history runs 7 years deep, the most recent figure standing at -$33.4 million for Q1 2026.

• Quarterly Net Cash Flow fell 404.99% year-over-year to -$33.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 104.7% YoY) and the FY2025 annual result came in at $19.1 million, up 85.79% from the prior year.
• Net Cash Flow was -$33.4 million for Q1 2026 at Jade Biosciences, down from $38.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $158.2 million in Q2 2025 and bottomed at -$170.8 million in Q3 2025.
• A 5-year average of $6.9 million and a median of -$2.9 million in 2022 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 5133.72% in 2023, while the deepest fall reached 39395.45% in 2023.
• Jade Biosciences' Net Cash Flow stood at -$22000.0 in 2022, then slumped by 39395.45% to -$8.7 million in 2023, then soared by 1049.65% to $82.5 million in 2024, then sank by 53.54% to $38.3 million in 2025, then sank by 187.03% to -$33.4 million in 2026.
• Business Quant data shows JBIO's Net Cash Flow at -$33.4 million in Q1 2026, $38.3 million in Q4 2025, and -$170.8 million in Q3 2025.